Receive Windhover's unique market insight fast with our free alert
service 'Windhover's Update', including the latest abstracts
and summaries from:
• IN VIVO
• Start-Up
• The RPM Report
• Medtech Insight
Sign up
now
|
|
|
To reach top decision makers in health care, advertise in
IN VIVO, Medtech Insight, START-UP, and The RPM Report.
| Call us
today for more information: |
Ken
May
Director, Commercial Sales
Elsevier Business Intelligence
Tel: (914) 332-1419
Mobile: (914) 356-5107
Email: k.may@elsevier.com |
Alicia F. McNiven
Director, Sponsorship & Advertising
Elsevier Business Intelligence
Tel: (215) 646-3778
Mobile: (908) 547-7262
Email: a.mcniven@elsevier.com |
|
|
 |
IN VIVO reaches top decision makers in the global health care marketplace with an authority no other publication can match.
IN VIVO has a 100% paid circulation base (annual subscription cost: $1550). The 10,000+ executives who get
IN VIVO every month read it because IN VIVO delivers unparalleled insight and analysis on company strategy, marketplace trends, key industry developments, and dealmaking.
|
Your advertisement in IN VIVO is delivered:
- To the highest level readership of key decision makers at health care products companies
- In a context unparalleled for credibility and insight
- At a cost significantly lower than other industry publications
View on-line media kit for IN VIVO advertising rates and demographics
(Adobe PDF Format)
 |
START-UP delivers your message to senior executives with committed interests in the emerging medical marketplace.
The 3,500+ executives who get START-UP every month read it because START-UP delivers expert analysis on the hottest companies, technologies, and trends affecting the emerging medical marketplace.
|
START-UP has 100% paid circulation base (annual subscription cost: $1350). Your advertisement in START-UP is delivered:
- To the highest level readership of key decision makers at health care products companies
- In a context unparalleled for credibility and insight
- At a cost significantly lower than other industry publications
View on-line media kit for START-UP advertising rates and demographics
(Adobe PDF Format)
 |
Medtech Insight newsletter delivers the highest quality content on medical technologies impacting the spectrum of surgical, orthopedic, cardiovascular and many other markets.
Top executives and investment professionals demand the Medtech Insight newsletter because it captures the perspectives of respected industry analysts, industry insiders, and clinicians to provide high-quality insights and analyses into the technologies impacting today’s global medical device marketplace.
|
Drivers and Opportunities for Novel Medical Technologies
Converging Medical Device, Biotech & Pharma Markets
Exclusive Content on Current & Emerging Medical Technologies
Latest Insider Information
Medtech Insight is published 10 times a year (including two combined issues)
View on-line media kit for Medtech Insight advertising rates and demographics
(Adobe PDF Format)
 |
The RPM Report: Regulation, Policy and Market Access delivers Biopharmaceutical executives engaged in gaining market access for their products. This 100% paid-circulation publication provides vital information on the regulatory, reimbursement and policy requirements to achieve commercial success.
|
View on-line media kit for The RPM Report advertising rates and demographics
(Adobe PDF Format)
|
|
 |
|
 |
|
|
| |
 |
Orphaned No Longer: Big Pharma Embraces Drugs for Niche Markets
Hit hard by late stage pipeline failures and the regulatory and reimbursement challenges of traditional primary care products, Big Pharmas are taking renewed interest in drugs for orphan diseases, where high unmet medical need offers the promise of premium pricing and there's potential to grow the market via approval in multiple indications. . . [MORE] (IN VIVO)
Despite Advances, Regenerative Medicine Faces Funding Crisis
Stem-cell and regenerative medicine firms are scrambling to find business models to harness the field's nascent, rapidly evolving science. Companies deep into clinical trials are still looking for pharma partnerships. . . [MORE] (Start-Up)
The Future of Drug-Eluting Stents Part II: Biodegradable Platforms
The safety profile of drug eluting stents appears to be improving with second and third-generation designs that utilize thinner struts (which are believed to reduce vessel injury and turbulent blood flow) and minimize or eliminate the polymer coating. . . [MORE] (Medtech Insight)
Health Reform in the Balance: What It Means for Biopharma
The long road to enacting health reform appeared to be close to an end with final negotiations taking place in the White House. But the Senate race for Ted Kennedy's open seat in Massachusetts has put the bill, and pharma's hard-fought concessions, in the breach. . . [MORE] (The RPM Report)
Read
more from the latest:
IN VIVO,
Start-Up,
The RPM Report,
Medtech Insight, "The Pink Sheet",
"The Pink Sheet" DAILY,
"The Rose Sheet",
"The Tan Sheet",
PharmAsia News,
Pharmaceutical Approvals Monthly, and
"The Gray Sheet".
|
|
|
|
| |
|
|
|
|
|
